Trials / Completed
CompletedNCT01221519
A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients
Randomized, Open, 4-way Crossover, Single Center, Phase I Relative Bioavailability Study in Type 2 Diabetes Mellitus Patients to Measure the Extent and Rate of Absorption of AZD1656 From Different Tablet Formulations
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1656 | 3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2010-10-15
- Last updated
- 2012-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01221519. Inclusion in this directory is not an endorsement.